ArticleDiscover oncology2024
A nomogram for enhanced risk stratification for predicting cervical lymph node metastasis in papillary thyroid carcinoma patients.
Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCervical lymph node metastasis (CLNM) significantly impacts the prognosis of papillary thyroid carcinoma (PTC) patients. Accurate CLNM prediction is crucial for surgical planning and patient outcomes. This study aimed to develop and validate a nomogram-based risk stratification system to predict CLNM in PTC patients.
methodsThis retrospective study included 1069 patients from Zhongshan Hospital and 253 from the Qingpu Branch of Zhongshan Hospital. Preoperative ultrasound (US) data and various nodule characteristics were documented. Patients underwent lobectomy with central lymph node dissection and lateral dissection if suspicious. Multivariate logistic regression, least absolute shrinkage and selection operator (LASSO) regression, and the random forest algorithm were used to identify CLNM risk factors. A nomogram was constructed and validated internally and externally. Model performance was assessed via receiver operating characteristic (ROC) curves, calibration plots, DeLong's test, decision curve analysis (DCA), and the clinical impact curve (CIC).
resultsSix independent CLNM risk factors were identified: age, sex, tumor size, calcification, internal vascularity, and US-reported CLNM status. The model's area under the curve (AUC) was 0.77 for both the training and the external validation sets. Calibration plots and Hosmer‒Lemeshow (HL) tests showed good calibration. The optimal cutoff value was 0.57, with a sensitivity of 58.02% and a specificity of 83.43%. Risk stratification on the basis of the nomogram categorized patients into low-, intermediate-, and high-risk groups, effectively differentiating the likelihood of CLNM, and an online calculator was created for clinical use.
conclusionThe nomogram accurately predicts CLNM risk in PTC patients, aiding personalized surgical decisions and improving patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.